Inactive Instrument

MolMed S.p.A.

Equities

MLM

IT0001080248

Biotechnology & Medical Research

MolMed S p A : KU awards PhD, M.Phil and MS Course Work degrees

December 03, 2019 at 07:05 am EST

The Advanced Studies and Research Board, University of Karachi, has awarded 34 PhD, 360 M.Phil and two Master of Surgery Course Work (30 Credit Hour) degrees in various disciplines.

The Registrar of Karachi University, Prof. Dr Saleem Shahzad here on Monday sharing details of the ASRB's recently held meeting , under the chairmanship of Vice Chancellor, Professor Dr Khalid Mahmood Irqai, said it was per recommendation of concerned supervisors and department heads that approval for award of these degrees. were made. As per decision PhD degrees were awarded to Fatima Rizvi (Pharmacology [BMSI]), Tahira Firdous (Islamic Learning), Abdul Rauf Shah, Perveen Akhtar and Mashhad Fatima (Chemistry), Shazia Sharafat and Shagufta Jahangir (Women Studies), Madiha Rehman and Meraj Zehra (Biochemistry).

Panira Ali, Muhammad Issa and Nuzhat Akram (European Studies), Mehr-un-Nisa (Economics), Bilqees Fatima Memon (Zoology), Imran Khan, Maria Kaleem, Sadaf Ismail and M. Bilal (Geography), Najia Mansoor (Pharmacology), Aliya Kashif (Geography [GIS]), Ruqaiya Khalil (Molecular Medicine), Fouzia Sohail (Applied Economics), Shahnaz Nasim and Shajeela Iram (Microbiology), Insia Hussain (Statistics), Hafiza Farhat Mutalib (Botany), Wajiha Gul, Rabya Munawar and Urooj Nazim (Pharmaceutical Chemistry), Muhammad Usman (Biochemistry [NCP]), Ayesha Zia (Clinical Psychology), Abeera Moin (Food Science and Technology), Syed Muzzamil Ahmed (Pharmacognosy) and Sarwat Afshan (Genetics). M.Phil degrees were said to be awarded to Wajid Ali (Islamic Learning), Gulgoona, Sanober Jamil, Tahira Khalid and Shabana Naz (Clinical Psychology), Syeda Anum Fatima and Salma (Pharmacology), Mehreen Shehzad, Wafa Mahmood and Roohina (Chemistry), Arshad, Shahid Iqbal and Javed Hussain (Commerce), Sidra Yousuf and M. Tabish (Marine Biology), Zaib un Nisa (Psychology), Zaitoon Kareem, Khalid Mahmood, Aqsa Sadaf and Tayyab Manzoor (Urdu), Sidra Fatima Hameedi.

Muhammad Ifrahim, Umm E Farwa, Salma Hassan, Khair Ullah, Rabia and Rameez Raja (Chemistry [HEJ]), Samia Mushtaq (Physiology), Hafiz Noman Khan (Islamic Studies [SZIC]), Tahira Mansoor (Biotechnology), Muna Shaheen (Microbiology), Waqar Ahmad (Applied Economics), Adil Shehzad (Genetics), Annam Akhtar (Botany), Itrat Waqar (Pharmaceutical Chemistry) and Munnum Zafar (Molecular Medicine). The KU Registrar, Dr Saleem Shahzad further said that the MS Course Work (30 credit hour) degrees were awarded to Zeba Salman and Farzana Naseem (Geography [GIS]).

Latest news about MolMed S.p.A.

Genenta Science S.p.A. and AGC Biologics S.p.A. Enter into A Development and Manufacturing Services Agreement	23-02-01	CI
AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies	22-12-12	CI
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies	22-08-16	CI
AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility	21-06-07	CI
MolMed Announces Transition of Luca Alberici from the Role of Chief Business Officer	20-10-12	CI
MolMed S.p.A.(BIT:MLM) dropped from S&P Global BMI Index	20-08-03	CI
AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €220 million.	20-07-23	CI
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration	20-07-09	CI
AGC : Italy to use vetting powers in Molmed acquisition by Japan's AGC	20-07-07	RE
AGC Inc. entered into an agreement to acquire MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €240 million.	20-03-16	CI
Molmed S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-08	CI
Molmed S.P.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-10	CI
Molmed S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2019	19-07-28	CI
Molmed S.P.A. Reports Earnings Results for Third Quarter and Nine Months Ended September 30, 2018	18-11-11	CI
MolMed S.p.A. and AbCheck s.r.o. Sign A Three-Year Master Agreement for the Development of New Cars Targeting Novel Tumor Antigens	18-06-28	CI
MolMed S.p.A. Announces Earnings Results for the First Quarter Ended March 31, 2018	18-05-10	CI
MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2017	18-03-08	CI
Molmed S.P.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-05	CI
MolMed S.p.A. announced that it has received funding from Société Générale Capital Partenaires SAS, SCR	17-09-20	CI
MolMed S.p.A. Announces Earnings Results for the Six Months Ended June 30, 2017	17-07-26	CI
MolMed S.p.A. and TTY Biopharm Company Ltd Announce Exclusive License and Distribution Agreement	17-07-03	CI
MolMed S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2017	17-05-07	CI
Megapharm Enters into Distribution and Licensing Agreement with MolMed for Zalmoxis	17-04-30	CI
MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2016	17-03-05	CI
MolMed S.p.A. announced that it expects to receive funding from Société Générale Capital Partenaires SAS, SCR	16-11-15	CI

Chart MolMed S.p.A.

Duration

Period

More charts

Company Profile

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company's activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue. MolMed's pipeline comprises two main investigational anticancer therapies: TK, which is a cell-based therapy for the treatment of leukemia, and NGR-hTNF, which is a biological drug targeting tumor blood vessels for the treatment of solid tumors. MolMed develops, conducts and validates custom studies, creating testing procedures and addressing the test specifications required for cell-based therapies. It is also active in the production of cell-based medicinal products used in clinical trials and drug development of cell-based therapies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+28.87%	49.18B
IQVIA HOLDINGS INC.	+1.11%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.72%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.19%	18.71B
BIO-TECHNE CORPORATION	+7.91%	13.26B
MEDPACE HOLDINGS, INC.	+32.48%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.75%	11.99B

Other Biotechnology & Medical Research